Join Growin Stock Community!

Crispr therapeutics agCRSP.US Overview

US StockHealthcare
(No presentation for CRSP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CRSP AI Insights

CRSP Overall Performance

CRSP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CRSP Recent Performance

-1.50%

Crispr therapeutics ag

0.05%

Avg of Sector

-0.31%

S&P500

CRSP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CRSP Key Information

CRSP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CRSP Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Price of CRSP

CRSP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CRSP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.06
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1644.60
PB Ratio
3.00
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-16569.77%
Revenue Growth (YoY)
-90.59%
Profit Growth (YoY)
-90.59%
3-Year Revenue Growth
424.15%
3-Year Profit Growth
424.15%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.06
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1644.60
PB Ratio
3.00
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-16569.77%
Revenue Growth (YoY)
-90.59%
Profit Growth (YoY)
-90.59%
3-Year Revenue Growth
424.15%
3-Year Profit Growth
424.15%

  • When is CRSP's latest earnings report released?

    The most recent financial report for Crispr therapeutics ag (CRSP) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CRSP's short-term business performance and financial health. For the latest updates on CRSP's earnings releases, visit this page regularly.

  • What is the operating profit of CRSP?

    According to the latest financial report, Crispr therapeutics ag (CRSP) reported an Operating Profit of -154.76M with an Operating Margin of -17,912.5% this period, representing a decline of 139.62% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CRSP's revenue growth?

    In the latest financial report, Crispr therapeutics ag (CRSP) announced revenue of 864K, with a Year-Over-Year growth rate of -97.58%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CRSP have?

    As of the end of the reporting period, Crispr therapeutics ag (CRSP) had total debt of 206.75M, with a debt ratio of 0.09. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CRSP have?

    At the end of the period, Crispr therapeutics ag (CRSP) held Total Cash and Cash Equivalents of 355.19M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CRSP go with three margins increasing?

    In the latest report, Crispr therapeutics ag (CRSP) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -17,912.5%%, and net margin of -15,117.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CRSP's profit trajectory and future growth potential.

  • Is CRSP's EPS continuing to grow?

    According to the past four quarterly reports, Crispr therapeutics ag (CRSP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.35. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CRSP?

    Crispr therapeutics ag (CRSP)'s Free Cash Flow (FCF) for the period is -93.07M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 85.09% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.